Milvexian clinical trials
Also written BMS-986177 and JNJ-70033093.
How each study uses milvexian is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 4 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 0
Bristol-Myers Squibb (14) · Janssen Research & Development, LLC (9) · Janssen Pharmaceutica N.V., Belgium (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test milvexian, phase 3 first.
- Dec 2026A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationPhase 3 · Janssen Research & Development, LLC
Studies
Open first, then newest update. How each study uses milvexian is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05757869Written as Milvexian
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEActive, not recruitingPhase 3Janssen Research & Development, LLCNCT05702034Written as Milvexian
- A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeCompletedPhase 3Janssen Research & Development, LLCNCT05754957Written as Milvexian
- A Study of JNJ-70033093 (Milvexian) in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04844424Written as Milvexian
- A Study of JNJ-70033093 (BMS-986177) in Healthy Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04223349Written as JNJ-70033093
- A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy ParticipantsCompletedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT04388501Written as Milvexian
- A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04569695Written as JNJ-70033093
- A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement SurgeryCompletedPhase 2Janssen Research & Development, LLCNCT03891524Written as JNJ-70033093 25 mg
- A Study of JNJ-70033093 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04448964Written as JNJ-70033093
- A Study of JNJ-70033093 and Digoxin in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04206488Written as JNJ-70033093
- A Study of Milvexian in Healthy Adult FemalesCompletedPhase 1Janssen Pharmaceutica N.V., BelgiumNCT05706753Written as Milvexian
- A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04965389Written as BMS-986177 Oral Solution
- A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelCompletedPhase 2Bristol-Myers SquibbNCT03766581Written as BMS-986177
- Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT03196206Written as BMS-986177
- A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT03698513Written as BMS-986177
- A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With HemodialysisCompletedPhase 1/2Bristol-Myers SquibbNCT03000673Written as BMS-986177
- Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03939702Written as BMS-986177
- Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT02982707Written as BMS-986177
- To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03224260Written as BMS-986177
- Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03362437Written as BMS-986177
See all 25 studies that test milvexian →
Given beside what is tested · 1 — milvexian is usual care or a partner of the new treatment
Codes
What other systems call milvexian · ClinicalTrials.gg INT001772
- MeSH (NLM) C000720754milvexianOne source NLM
- UNII (FDA) 0W79NDQ608MILVEXIANConfirmed FDA, NLM, Wikidata
- Wikidata Q109655049milvexianConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175138MilvexianOne source FDA
- DrugBank DB16233One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720754 | milvexian | One source NLM |
| UNII (FDA) | 0W79NDQ608 | MILVEXIAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q109655049 | milvexian | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175138 | Milvexian | One source FDA |
| DrugBank | DB16233 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.